Literature DB >> 18445613

Coronary collaterals in obese patients: impact of metabolic syndrome.

Hatice Sasmaz1, Mehmet Birhan Yilmaz.   

Abstract

Obesity is a growing pandemic. Among obese patients with significant coronary artery stenosis, development of coronary collaterals was investigated. Consecutive 104 obese patients with stable angina pectoris were enrolled. Coronary collaterals were assessed according to the Cohen and Rentrop grading system and classified into 2 as those with poor collaterals (grade 0-1, Group 1) and those with good collaterals (grade 2-3, Group 2). Group 1 had higher body mass index, shorter duration of angina pectoris than Group 2. Poor collaterals were present in 82.3% and 59.5% of patients with and without (P = .019) metabolic syndrome, respectively. Metabolic syndrome score (sum of each component) was found to be negatively correlated with Rentrop score (r = -691; P < .001). After controlling for symptom duration and body mass index, metabolic syndrome kept independent association with poor collaterals among obese patients (P = .043, B = 1.8). Metabolic syndrome appears to influence the development of coronary collaterals among obese patients with stable coronary artery disease.

Entities:  

Mesh:

Year:  2008        PMID: 18445613     DOI: 10.1177/0003319708316007

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  9 in total

1.  miR-21 normalizes vascular smooth muscle proliferation and improves coronary collateral growth in metabolic syndrome.

Authors:  Rebecca Hutcheson; Jennifer Chaplin; Brenda Hutcheson; Faye Borthwick; Spencer Proctor; Sarah Gebb; Rashmi Jadhav; Erika Smith; James C Russell; Petra Rocic
Journal:  FASEB J       Date:  2014-06-05       Impact factor: 5.191

Review 2.  Why is coronary collateral growth impaired in type II diabetes and the metabolic syndrome?

Authors:  Petra Rocic
Journal:  Vascul Pharmacol       Date:  2012-02-09       Impact factor: 5.773

3.  Elevated 20-HETE impairs coronary collateral growth in metabolic syndrome via endothelial dysfunction.

Authors:  Gregory Joseph; Amanda Soler; Rebecca Hutcheson; Ian Hunter; Chastity Bradford; Brenda Hutcheson; Katherine H Gotlinger; Houli Jiang; John R Falck; Spencer Proctor; Michal Laniado Schwartzman; Petra Rocic
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-12-23       Impact factor: 4.733

4.  MicroRNA-145 restores contractile vascular smooth muscle phenotype and coronary collateral growth in the metabolic syndrome.

Authors:  Rebecca Hutcheson; Russell Terry; Jennifer Chaplin; Erika Smith; Alla Musiyenko; James C Russell; Thomas Lincoln; Petra Rocic
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-02-07       Impact factor: 8.311

5.  Metabolic syndrome and its components reduce coronary collateralization in chronic total occlusion: An observational study.

Authors:  Tong Liu; Zheng Wu; Jinghua Liu; Yun Lv; Wenzheng Li
Journal:  Cardiovasc Diabetol       Date:  2021-05-10       Impact factor: 9.951

Review 6.  The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration.

Authors:  Rebecca Hutcheson; Petra Rocic
Journal:  Exp Diabetes Res       Date:  2012-07-09

7.  A device for performing automated balloon catheter inflation ischemia studies.

Authors:  Silas J Leavesley; Whitley Ledkins; Petra Rocic
Journal:  PLoS One       Date:  2014-04-25       Impact factor: 3.240

Review 8.  Mechanisms of Comorbidities Associated With the Metabolic Syndrome: Insights from the JCR:LA-cp Corpulent Rat Strain.

Authors:  Abdoulaye Diane; W David Pierce; Sandra E Kelly; Sharon Sokolik; Faye Borthwick; Miriam Jacome-Sosa; Rabban Mangat; Jesus Miguel Pradillo; Stuart McRae Allan; Megan R Ruth; Catherine J Field; Rebecca Hutcheson; Petra Rocic; James C Russell; Donna F Vine; Spencer D Proctor
Journal:  Front Nutr       Date:  2016-10-10

Review 9.  The Role of High-Density Lipoproteins in Endothelial Cell Metabolism and Diabetes-Impaired Angiogenesis.

Authors:  Khalia R Primer; Peter J Psaltis; Joanne T M Tan; Christina A Bursill
Journal:  Int J Mol Sci       Date:  2020-05-21       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.